Showing 2768 results
-
Press release /Regardless of body mass index (BMI), Leqvio provided sustained and effective LDL-C reduction of ~50% with two doses a year**, according to pooled analysis of three Phase III studies 1Being overweight…
-
Press release /HER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…
-
Press release /Treatment with Cosentyx® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Ad hoc release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der…
-
Press release /Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory (r/r) follicular…
-
Press release /Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous…
-
Pulse Update /
-
Pulse Update /
-
Statement /